Inify Laboratories: Notice of Extraordinary General Meeting and proposed fully guaranteed equity issue with proceeds of SEK 150 million

15 Nov 2024 12:00 CET

STOCKHOLM - November 15, 2024 - reference is made to the stock exchange
announcement made by Inify Laboratories AB ("Inify" or the "Company") on 23
October 2024 regarding expansion to the UK and a potential share issue of
approximately SEK 150 million.

The Company will in a separate press release call for an Extraordinary General
Meeting (the "EGM") to be held on 6 December 2024 at 10:00 CET to resolve to
authorize the board of directors to resolve on the issuance of new shares.
Provided that the EGM resolves to authorize the board of directors to resolve on
the issuance of new shares, the intention is to utilise the authorization to
resolve on (i) a fully guaranteed private placement of the NOK equivalent of
approximately SEK 135 million with a minimum subscription per subscriber of the
SEK equivalent of EUR 100,000 directed pro-rata towards existing shareholders
holding more than 400,000 shares in the Company (the "Private Placement"), and
(ii) a fully guaranteed repair issue of the NOK equivalent of approximately SEK
15 million (the "Repair Issue"), directed pro-rata towards existing shareholders
with less than 400,000 shares. The price per share in the Private Placement and
the Repair Issue will be NOK 4.50.

Monsun AS and Auris AS (the "Guarantors"), companies controlled by the same
owners as the two largest shareholders Gallivant S.à r.l. ("Gallivant") and
Tauri AS ("Tauri"), respectively, have entered into guarantee undertakings
covering in total 100% of the Private Placement and the Repair Issue (the
"Guarantee Commitment"). The Guarantors will not receive any compensation for
the Guarantee Commitment.

Any existing shareholder participating in the Private Placement and the Repair
Issue can expect to retain their pro-rata ownership, provided that they
subscribe for an amount sufficient to their pro-rata ownership in the Company.

The application period in the Private Placement is expected to commence shortly
after the EGM, if the EGM successfully resolves to authorize the board of
directors to resolve on the issuance of new shares.

Following the completion of the Private Placement, the Company will publish a
national (Norwegian) prospectus and commence the Repair Issue. The Repair Issue
will be directed towards existing shareholders with less than 400,000 shares
and. The national (Norwegian) prospectus is expected to be published in the
beginning of January 2025, with a two-week application period thereafter.

The combined proceeds from the Private Placement and the Repair Issue will be
the NOK equivalent of approximately SEK 150 million before transaction costs and
will be used to fund Inify's expansion into the UK and for general working
capital.

Additional information about the Private Placement and Repair Issue will be
published in due course.

For further information, please contact CEO, Fredrik Palm,
fredrik.palm@inify.com, or visithttps://www.inify.com

Advisors

SpareBank1 Markets AS ("SpareBank1 Markets") has been appointed as financial
advisor in connection with the Private Placement and the Repair Issue. Schjødt
law firm acts as legal counsel to the Company.

###

The future of pathology

Inify Laboratories provides cancer diagnostics through ultramodern laboratory
services within pathology. It uses a fully digital, standardized and AI-
supported workflow to optimize quality and response times, initially within
prostate.The concept is scalable and can be extended to other diagnoses.
The service includes the whole chain of sample handling: from logistics, to
sample preparation, to reporting by a pathologist. The report is assisted by our
own AI, proven in clinical studies to have world-leading accuracy. The complete
workflow is supported by a tailor-made process control system.
The company, based in Sweden, became independent in 2022 through a spin-off
fromContextVision (https://www.contextvision.com/), with 40 years of experience
within digital imaging for medical applications. It is listed onEuronext Growth
Oslo under the ticker
INIFY (https://live.euronext.com/en/product/equities/SE0017486103-MERK).

###

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation (MAR) and is subject to the disclosure requirements
pursuant to MAR article 17 and section 5-12 the Norwegian Securities Trading
Act.

This stock exchange announcement was published by Ann-Charlotte Linderoth, Inify
Laboratories AB on the time and date provided.

###

Important information

The release, announcement or distribution of this press release may, in certain
jurisdictions, be subject to restrictions. The recipients of this press release
in jurisdictions where this press release has been published or distributed
shall inform themselves of and follow such restrictions. The recipient of this
press release is responsible for using this press release, and the information
contained herein, in accordance with applicable rules in each jurisdiction. The
information in this press release does not contain or constitute an offer to
acquire, subscribe or otherwise trade in shares, subscription rights or other
securities in The Company in any jurisdiction. Any invitation to the persons
concerned to subscribe for shares in the Repair Issue will only be made through
the national (Norwegian) prospectus which the Company expects to publish in the
beginning of January 2025.

This press release does not identify or suggest, or purport to identify or
suggest, the risks (direct or indirect) that may be associated with an
investment in new shares. Any investment decision in connection with the Private
Placement and Repair Issue must be made on the basis of all publicly available
information relating to the Company and the Company's shares. Such information
has not been independently verified by SpareBank1 Markets. The information
contained in this announcement is for background purposes only and does not
purport to be full or complete. No reliance may be placed for any purpose on the
information contained in this announcement or its accuracy or completeness.
SpareBank1 Markets is acting for the Company in connection with the transaction
and no one else and will not be responsible to anyone other than the Company for
providing the protections afforded to its clients nor for giving advice in
relation to the transaction or any other matter referred to herein.

This press release does not constitute a recommendation concerning any
investor's option with respect to the Private Placement and Repair Issue. Each
investor or prospective investor should conduct his, her or its own
investigation, analysis and evaluation of the business and data described in
this announcement and publicly available information. The price and value of
securities can go down as well as up. Past performance is not a guide to future
performance.

The information contained in this press release is not intended for, and must
not be accessed by, or distributed or disseminated, directly or indirectly, in
whole or in part, to persons resident or physically present in the United States
of America (including its territories and possessions, any state of the United
States and the District of Columbia) (the "United States"), Australia, Canada,
Hong Kong, Japan, New Zealand, Singapore, South Africa, United Kingdom or any
other jurisdiction where such action is wholly or partially subject to legal
restrictions, or would require additional prospectuses, registration or other
measures than those required by Swedish law. The information in the press
release does not constitute any offer regarding subscription rights, paid
subscribed shares or shares in the Company ("Securities") to any person in said
jurisdictions. The information in the press release may not be forwarded or
reproduced in such a manner that contravenes such restrictions or gives cause to
such requirements.

No securities have been or will be registered under the United States Securities
Act of 1933, as amended (the "Securities Act") or the securities legislation of
any state or other jurisdiction in the United States and may not be offered,
subscribed for, exercised, used, pledged, sold, resold, granted, delivered or
otherwise transferred, directly or indirectly, in or into the United States
except pursuant to an applicable exemption from, or in a transaction not subject
to, the registration requirements under the Securities Act and in compliance
with the securities legislation in the relevant state or any other jurisdiction
of the United States.

Within the European Economic Area ("EEA"), no public offering of Securities is
made in other countries than Sweden or Norway. In other member states of the EU,
such an offering of Securities may only be made in accordance with the
Prospectus Regulation (EU) 2017/1129 (the "Prospectus Regulation"). In other
member states of the EEA which have implemented the Prospectus Regulation in its
national legislation, any offer of Securities may only be made in accordance
with an applicable exemption in the Prospectus Regulation and/or in accordance
with an applicable exemption under a relevant national implementation measure.

In the United Kingdom, this document and any other materials in relation to the
securities described herein is only being distributed to, and is only directed
at, and any investment or investment activity to which this document relates is
available only to, and will be engaged in only with, "qualified investors" who
are (i) persons having professional experience in matters relating to
investments who fall within the definition of "investment professionals" in
Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (the "Order"); or (ii) high net worth entities falling
within Article 49(2)(a) to (d) of the Order (all such persons together being
referred to as "relevant persons"). In the United Kingdom, any investment or
investment activity to which this communication relates is available only to,
and will be engaged in only with, relevant persons. Persons who are not relevant
persons should not take any action on the basis of this press release and should
not act or rely on it.

Forward-looking statements

This press release contains forward-looking statements that reflect the
Company's intentions, beliefs, or current expectations about and targets for the
Company's future results of operations, financial condition, liquidity,
performance, prospects, anticipated growth, strategies and opportunities and the
markets in which the Company's operates. Forward-looking statements are
statements that are not historical facts and may be identified by words such as
"believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will",
"should", "could", "aim" or "might", or, in each case, their negative, or
similar expressions. The forward-looking statements in this press release are
based upon various assumptions, many of which are based, in turn, upon further
assumptions. Although the Company believes that the expectations reflected in
these forward-looking statements are reasonable, it can give no assurances that
they will materialize or prove to be correct. Because these statements are based
on assumptions or estimates and are subject to risks and uncertainties, the
actual results or outcome could differ materially from those set out in the
forward-looking statements as a result of many factors. Such risks,
uncertainties, contingencies and other important factors could cause actual
events to differ materially from the expectations expressed or implied in this
release by such forward-looking statements. The Company does not guarantee that
the assumptions underlying the forward-looking statements in this press release
are free from errors and readers of this press release should not place undue
reliance on the forward-looking statements in this press release. The
information, opinions and forward-looking statements that are expressly or
implicitly contained herein speak only as of its date and are subject to change
without notice. Neither the Company nor anyone else undertake to review, update,
confirm or to release publicly any revisions to any forward-looking statements
to reflect events that occur or circumstances that arise in relation to the
content of this press release.

Information to distributors

Solely for the purposes of the product governance requirements contained within:
(a) EU Directive 2014/65/EU on markets in financial instruments, as amended
("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU)
2017/593 supplementing MiFID II; and (c) local implementing measures (together,
the "MiFID II Product Governance Requirements"), and disclaiming all and any
liability, whether arising in tort, contract or otherwise, which any
"manufacturer" (for the purposes of the MiFID II Product Governance
Requirements) may otherwise have with respect thereto, the shares in the Company
have been subject to a product approval process, which has determined that such
shares are: (i) compatible with an end target market of retail investors and
investors who meet the criteria of professional clients and eligible
counterparties, each as defined in MiFID II; and (ii) eligible for distribution
through all distribution channels as are permitted by MiFID II (the "Target
Market Assessment"). Notwithstanding the Target Market Assessment, Distributors
should note that: the price of the shares in the Company may decline and
investors could lose all or part of their investment; the shares in The Company
offer no guaranteed income and no capital protection; and an investment in the
shares in the Company is compatible only with investors who do not need a
guaranteed income or capital protection, who (either alone or in conjunction
with an appropriate financial or other adviser) are capable of evaluating the
merits and risks of such an investment and who have sufficient resources to be
able to bear any losses that may result therefrom. The Target Market Assessment
is without prejudice to the requirements of any contractual, legal or regulatory
selling restrictions in relation to the new share issue. Furthermore, it is
noted that, notwithstanding the Target Market Assessment, SpareBank1 Markets
will only procure investors who meet the criteria of professional clients and
eligible counterparties.

For the avoidance of doubt, the Target Market Assessment does not constitute:
(a) an assessment of suitability or appropriateness for the purposes of MiFID
II; or (b) a recommendation to any investor or group of investors to invest in,
or purchase, or take any other action whatsoever with respect to the shares in
the Company.

Each distributor is responsible for undertaking its own target market assessment
in respect of the shares in the Company and determining appropriate distribution
channels.

More information:
Access the news on Oslo Bors NewsWeb site

632377_Inify_Laboratories_Notice_of_EGM_and_proposed_equity_issue.pdf